CEBPA and acute myeloid leukemia: AML with the following gene mutations have also been included: NPM1, CEBPA (biallelic), BCR-ABL1, and RUNX1. AML with NPM1 or biallelic CEBPA mutations are considered favorable while AML with RUNX1 mutations are unfavorable.21,22